164 related articles for article (PubMed ID: 24399579)
1. Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment.
Perlman RL; Rao PS
Drugs Aging; 2014 Feb; 31(2):103-9. PubMed ID: 24399579
[TBL] [Abstract][Full Text] [Related]
2. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens.
Hathaway D; Winsett R; Prendergast M; Subaiya I
Clin Transplant; 2003 Jun; 17(3):183-94. PubMed ID: 12780666
[TBL] [Abstract][Full Text] [Related]
3. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ
J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion.
Reimer J; Franke GH; Philipp T; Heemann U
Clin Transplant; 2002 Feb; 16(1):48-54. PubMed ID: 11982615
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus and quality of life after kidney transplantation--a multicenter study.
Bohlke M; Rocha M; Gomes RH; Marini SS; Terhorst L; Barcellos FC; Hallal PC; Casarini D; Irigoyen MC
Clin Transplant; 2006; 20(4):504-8. PubMed ID: 16842529
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
7. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
[No Abstract] [Full Text] [Related]
8. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
9. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
[TBL] [Abstract][Full Text] [Related]
10. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
[TBL] [Abstract][Full Text] [Related]
11. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
[TBL] [Abstract][Full Text] [Related]
12. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation.
Franke GH; Trampenau C; Reimer J;
Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
[TBL] [Abstract][Full Text] [Related]
14. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60.
Xenos EX; Ciancio G; Burke GW; Roth D; Miller J
Clin Transplant; 1997 Oct; 11(5 Pt 2):497-9. PubMed ID: 9361949
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.
Ahlenstiel-Grunow T; Pape L
Pediatr Nephrol; 2020 Apr; 35(4):625-631. PubMed ID: 31858227
[TBL] [Abstract][Full Text] [Related]
16. One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation.
Pascual J; Marcén R; Burgos FJ; Tenorio MT; Merino JL; Arambarri M; Villafruela JJ; Liaño F; Mampaso F; Ortuño J
Transplant Proc; 2002 Feb; 34(1):94-5. PubMed ID: 11959200
[No Abstract] [Full Text] [Related]
17. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression in older renal transplant patients.
Morales JM; Campistol JM; Andrés A; Herrero JC
Drugs Aging; 2000 Apr; 16(4):279-87. PubMed ID: 10874523
[TBL] [Abstract][Full Text] [Related]
20. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
